Alnylam’s treatment did not significantly lower blood pressure in mid-stage study
An investigational therapy from Alnylam Pharmaceuticals did not significantly lower blood pressure in a key Phase 2 trial, raising questions about the benefit of the twice-a-year treatment as it enters late-stage testing. Among high-risk patients already taking at least two common hypertension treatments, a 300-mg dose of Alnylam’s zilebesiran led to a reduction in blood … [Read more…]